Home: PCU
4|2003: CME Audio Series
Prostate Cancer Update: A CME Audio Series and Activity
STATEMENT OF NEED/TARGET AUDIENCE
Prostate cancer is one of the most rapidly evolving fields in urology. Published
results from
clinical trials lead to the emergence of new surgical and radiation therapy
techniques and
therapeutic agents, along with changes in the indications for existing treatments.
In order to offer
optimal patient care — including the option of clinical trial participation — the
practicing
urologist and radiation oncologist must be well-informed of these advances.
To bridge the gap
between research and patient care, Prostate Cancer Update utilizes one-on-one
discussions with
leading urologic oncology investigators. By providing access to the latest
research developments
and expert perspectives, this CME program assists urologists and radiation
oncologists in the
formulation of up-to-date clinical management strategies.
GLOBAL LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Critically evaluate the clinical implications of emerging clinical trial
data in prostate cancer
treatment.
- Inform patients about the specific risks and benefits of local and systemic
therapies.
- Provide individualized counseling to patients regarding the choice and
timing of endocrine
therapy.
- Offer patients information regarding their prognosis with and without
various therapeutic
options.
Issue 4, 2003, of Prostate Cancer Update consists of discussions
with three research leaders on a
variety of important issues, including timing and duration of total
androgen blockade, prostate-specific
antigen (PSA) relapse, brachytherapy and several interesting case
discussions.
SPECIFIC LEARNING OBJECTIVES FOR ISSUE 4
Upon completion of this activity, participants should be able to:
- Counsel prostate cancer patients about the results of the RTOG-9413 trial
of whole-pelvic radiation
therapy and neoadjuvant combined androgen suppression.
- Define the risk subsets for patients who are candidates for long-term
hormone therapy after initial
therapy with radiation.
-
Review clinical trial data and research leaders’ perspectives about
early versus delayed hormonal
therapy in order to counsel patients with postprostatectomy
biochemical failure.
- Describe ongoing clinical trials evaluating adjuvant chemotherapy in
order to counsel patients with
high-risk prostate cancer about participation.
- Counsel patients about the sexual outcomes associated with the various
treatment alternatives for
localized prostate cancer and the success and treatment
adherence rates for the therapeutic
options for erectile dysfunction.
ACCREDITATION STATEMENT
NL Communications Inc is accredited by the Accreditation
Council for Continuing Medical
Education (ACCME) to provide continuing medical education
for physicians.
CREDIT DESIGNATION STATEMENT
NL Communications Inc designates this educational activity
for a maximum of 3 category 1 credits
toward the AMA Physician’s Recognition Award.
Each physician should claim only credits that he/she
actually spent on the activity.
|
